Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

被引：1

作者：

Delimpasi, Sosana ^{[1
,2
]}

Dimopoulos, Meletios A. ^{[3
]}

Straub, Jan ^{[4
]}

Symeonidis, Argiris ^{[5
]}

Hajek, Roman ^{[6
,7
]}

Touzeau, Cyrille ^{[8
]}

Bhanderi, Viralkumar K. ^{[9
]}

Berdeja, Jesus ^{[10
]}

Pavlicek, Petr ^{[11
]}

Matous, Jeffrey, V ^{[12
,13
]}

Robak, Pawel J. ^{[14
,15
]}

Suryanarayan, Kaveri ^{[16
]}

Villareal, Miguel ^{[16
]}

Cherepanov, Dasha ^{[1
,2
,3
]}

Srimani, Jaydeep K. ^{[16
]}

Yao, Huilan ^{[16
]}

Labotka, Richard ^{[16
]}

Orlowski, Robert Z. ^{[17
,18
]}

机构：

[1] Gen Hosp Evangelismos, Dept Hematol, Athens, Greece

[2] Gen Hosp Evangelismos, Bone Marrow Transplantat Unit, Athens, Greece

[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece

[4] Univ Hosp, Dept Internal Med Hematol, Prague, Czech Republic

[5] Univ Gen Hosp Patras, Dept Hematol, Patras, Greece

[6] Univ Hosp Ostrava, Ostrava, Czech Republic

[7] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[8] Univ Hosp Hotel Dieu, Nantes, France

[9] Tallahassee Canc Ctr, Florida Canc Specialists, Tallahassee, FL USA

[10] Sarah Cannon Res Inst, Nashville, TN USA

[11] Univ Hosp Kralovske Vinohrady, Dept Internal Med & Hematol, Prague, Czech Republic

[12] Colorado Blood Canc Inst, Denver, CO USA

[13] Sarah Cannon Res Inst, Denver, CO USA

[14] Med Univ Lodz, Dept Hematol, Lodz, Poland

[15] Copernicus Mem Hosp, Lodz, Poland

[16] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163092

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：9995 / 9997

页数：3

共 50 条

[1] Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1-3 prior therapies: phase 2 study interim analysis (IA)
Orlowski, Robert
Delimpasi, Sosana
Straub, Jan
Symeonidis, Argiris
Pour, Ludek
Hajek, Roman
Touzeau, Cyrille
Bhanderi, Viralkumar
Pavlicek, Petr
Robak, Pawel
Berdeja, Jesus G.
Matous, Jeffrey V.
Karlin, Lionel
Zweegman, Sonja
Grosicki, Sebastian
Pluta, Andrzej
Kambhampati, Suman
Suryanarayan, Kaveri
Twumasi-Ankrah, Philip
Dash, Ajeeta
Labotka, Richard
Dimopoulos, Meletios-Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S155
[2] LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).
Mateos, Maria-Victoria
Pour, Ludek
Ocio, Enrique M.
Sonneveld, Pieter
Blixt, Catarina Jansson
Larsson, Kajsa
Palmer, Linda
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
Sonneveld, Pieter
Terpos, Evangelos
Dimopoulos, Meletios A.
Ukropec, Jon
Smith, Elena
Houkes, Nienke
Schecter, Jordan Mark
Kastritis, Efstathios
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma
Delimpasi, Sosana
Dimopoulos, Meletios A.
Straub, Jan
Symeonidis, Argiris
Pour, Ludek
Hajek, Roman
Touzeau, Cyrille
Bhanderi, Viralkumar K.
Berdeja, Jesus G.
Pavlicek, Petr
Matous, Jeffrey V.
Robak, Pawel J.
Suryanarayan, Kaveri
Miller, Alison
Villarreal, Miguel
Cherepanov, Dasha
Srimani, Jaydeep K.
Yao, Huilan
Labotka, Richard
Orlowski, Robert Z.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1746 - 1756
[5] Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
Mateos, Maria-Victoria
Nahi, Hareth
Legiec, Wojciech
Grosicki, Sebastian
Vorobyev, Vladimir
Spicka, Ivan
Hungria, Vania T. M.
Korenkova, Sibirina
Bahlis, Nizar J.
Flogegard, Max
Blade, Joan
Moreau, Philippe
Kaiser, Martin
Iida, Shinsuke
Laubach, Jacob
Ahmadi, Tahamtan
Parasrampuria, Dolly A.
Peng, Lixian
Qi, Ming
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
Chari, Ajai
Lonial, Sagar
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
Oriol, Albert
Otero, Paula Rodriguez
Pineiro, Luis
Jakubowiak, Andrzej
Olyslager, Yunsi
Wang, Jianping
Nnane, Ivo
Ukropec, Jon
Shreeve, Martin
Qi, Ming
Moreau, Philippe
BLOOD, 2019, 134
[7] Final results for the 1703 phase 1b/2 study of Elotuzumab (Elo) in combination with Lenalidomide (Len) and dexamethasone (dex) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Raab, M. S.
Richardson, P. G.
Jagannath, S.
Moreau, P.
Jakubowiak, A. J.
Facon, T.
Vij, R.
White, D.
Reece, D. E.
Benboubker, L.
Zonder, J.
Tsao, L. C.
Anderson, K. C.
Bleickardt, E.
Singhal, A. K.
Lonial, S.
Oncology Research and Treatment, 2015, 38 : 165 - 165
[8] Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.
Mateos, Maria-Victoria
Masszi, Tamas
Grzasko, Norbert
Hansson, Markus
Sandhu, Irwindeep
Pour, Ludek
Viterbo, Luisa
Jackson, Sharon R.
Stoppa, Anne-Marie
Gimsing, Peter
Hamadani, Mehdi
Borsaru, Gabriela
Berg, Deborah
Lin, Jianchang
Van De Velde, Helgi
Richardson, Paul G.
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma RRMM)
Kumar, Shaji
Grzasko, Norbert
Delimpasi, Sossana
Jedrzejczak, Wieslaw
Grosicki, Sebastian
Kyrtsonis, Marie Christine
Spencer, Andrew
Gupta, Neeraj
Teng, Zhaoyang
Byrne, Catriona
Labotka, Richard
Dimopoulos, Meletios Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E131 - E131
[10] Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study
Stege, Claudia A. M.
Nasserinejad, Kazem
van der Spek, Ellen
Van Kampen, Roel J. W.
Sohne, Maaike
Thielen, Noortje
Bilgin, Yavuz
De Waal, Esther G. M.
Ludwig, Inge
Leijs, Maria B. L.
Kentos, Alain
Timmers, Gert Jan
de Heer, Koen
Westerman, Matthijs
Vekemans, Marie Christiane
Durdu-Rayman, Nazik
van der Burg-de Graauw, Nicole C. H. P.
Van de Donk, Niels W. C. J.
Sonneveld, Pieter
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
BLOOD, 2019, 134

← 1 2 3 4 5 →